Skip to content
AnalystLens

QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 19, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed March 19, 2025
Period End
March 19, 2025
Security
DGX
In the record · 2016–202610-K1110-Q328-K132

DGX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 132 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’16May ’16
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed March 19, 2025. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) held its 2025 Investor Day on March 19, 2025, using the event to lay out strategies for sustainable growth and a long-term financial outlook beyond 2025.

Management projects revenue growth of 4-5% CAGR and adjusted diluted EPS growth of 7-9% CAGR beyond 2025. Importantly, the company reaffirmed its full-year 2025 guidance, which calls for net revenues of $10.70a-$10.85 billion (8.4%-9.9% growth), reported diluted EPS of $8.34-$8.59, and adjusted diluted EPS of $9.55-$9.80, alongside operating cash flow of roughly $1.45 billion and capital expenditures of roughly $500 million. The strategic framework centers on above-market growth in physician and hospital channels, double-digit growth in advanced diagnostics across five clinical areas (oncology, cardiometabolic health, women's health, brain health, and autoimmune disorders), and contributions from strategic partnerships and acquisitions.

Operational initiatives include a 3%b annual productivity and cost-savings program (Invigorate), automation/AI investments, and Project Nova, a multi-year IT modernization effort intended to lower long-term IT costs. Management also stated a capital allocation policy of returning the majority of free cash flow to shareholders while funding strategic investments and acquisitions.

A notable near-term caveat is that worse-than-anticipated first-quarter 2025 weather is expected to reduce revenue by about $25 millionc and EPS by about $0.10. The filing is a Regulation FD disclosure, so the materials are furnished rather than filed, and the long-term targets are forward-looking and subject to the risks listed in the company's SEC filings.

02—Key points

Key Highlights

  1. Long-term outlook beyond 2025: revenue CAGR of 4-5% and adjusted diluted EPS CAGR of 7-9%.
  2. Full-year 2025 guidance reaffirmed: net revenues of $10.70-$10.85 billion (8.4%-9.9% growth) and adjusted diluted EPS of $9.55-$9.80.
  3. Reported diluted EPS guidance of $8.34-$8.59; cash from operations of about $1.45 billion and capex of about $500 million.
  4. Q1 2025 headwind: worse-than-anticipated weather expected to reduce revenue by about $25 million and EPS by about $0.10.
  5. Growth drivers include double-digit advanced diagnostics growth in five clinical areas and above-market growth in physician and hospital channels.
  6. Cost and efficiency programs: 3% annual productivity and cost savings (Invigorate) and Project Nova IT modernization to lower long-term IT costs.
  7. Capital allocation priority: return the majority of free cash flow to shareholders while funding acquisitions and strategic investments.

03—Questions

Frequently Asked Questions

  1. Did Quest change its 2025 guidance at Investor Day?

    No. Quest reaffirmed its full-year 2025 guidance, with net revenues of $10.70-$10.85 billion, reported diluted EPS of $8.34-$8.59, and adjusted diluted EPS of $9.55-$9.80. The only near-term change was a flagged Q1 2025 weather headwind of about $25 million in revenue and $0.10 in EPS.

  2. What long-term growth targets did management provide?

    Management expects revenue to grow at a 4-5% compound annual growth rate and adjusted diluted EPS at a 7-9% CAGR beyond 2025. These are forward-looking targets, and the company notes it cannot reconcile the adjusted EPS outlook to GAAP EPS because special items are uncertain.

  3. What is driving the growth strategy?

    Key drivers include above-market growth in physician and hospital channels, expanded health plan network access, hospital lab outreach acquisitions, and double-digit growth in advanced diagnostics such as oncology (Haystack MRD) and brain health (AD-Detect). Operational efficiency comes from automation, robotics, AI, the Invigorate productivity program, and Project Nova.

  4. How does the adjusted EPS guidance differ from reported EPS?

    Adjusted EPS excludes items such as restructuring and integration charges (about $0.11), amortization expense (about $1.05), other charges including contingent consideration fair value changes (about $0.13), and an excess tax benefit from stock compensation (about -$0.08). Together these bridge reported EPS of $8.34-$8.59 to adjusted EPS of $9.55-$9.80.

04—Continue

← View all 8-K filings